Evidence map›Paper›PMID 42742485›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Relaxin-2: Shaping the Proteomic Landscape of Skeletal Muscle Physiology, Glucose Trafficking, and Mitochondrial Function in Rat.

Xocas Vázquez-Abuín, Lucía Gómez-Cibeira, Javier García-Seara, Pablo de la Fuente-López, Carlos Minguito-Carazo, Susana B Bravo, Manuel Otero-Santiago, Oreste Gualillo, José Ramón González-Juanatey, Francisca Lago and 2 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xocas Vázquez-AbuínCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0009-0009-8744-7799
Lucía Gómez-CibeiraCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0009-0009-7050-9455
Javier García-SearaCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0001-7903-9490
Pablo de la Fuente-LópezCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-1264-8256
Carlos Minguito-CarazoCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-3628-6245
Susana B BravoProteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0001-7615-3079
Manuel Otero-SantiagoCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-9769-8761
Oreste GualilloLaboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-7154-1328
José Ramón González-JuanateyCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0001-9681-3388
Francisca LagoCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-4593-8399
Sandra Feijóo-BandínCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-3739-5806
Alana Aragón-HerreraCellular and Molecular Cardiology Research Unit, IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela), Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0003-3089-0684

Funding

Axencia Galega de Innovación (GAIN) GPC IN607B 2024/02Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV)Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)MEC | Instituto de Salud Carlos III (ISCIII) CD24/00140MEC | Instituto de Salud Carlos III (ISCIII) FI25/00032MEC | Instituto de Salud Carlos III (ISCIII) PI24/00114MEC | Instituto de Salud Carlos III (ISCIII) PI24/01264Sociedad Española de Cardiología (Spanish Society of Cardiology) RLD_SEC2016Sociedad Española de Cardiología (Spanish Society of Cardiology) SECAINC-INV-ICC 23/02Sociedad Española de Cardiología (Spanish Society of Cardiology) SECAINC-INV-ICC 25/02the European Union
6 · The paper itself

Abstract

Relaxin-2 is a hormone with robust beneficial effects on the heart and blood vessels and potential as a therapy for cardiovascular (CV) disease. Considering the interorgan communication between skeletal muscle and heart, and the relation between muscle quality/composition and CV events, we hypothesize that relaxin-2 may regulate skeletal muscle physiology and metabolism. We aim to evaluate the impact of relaxin-2 on the proteome of skeletal muscle from healthy Sprague-Dawley rats. Animals were treated with 0.4 mg/kg/day of serelaxin (recombinant form of human relaxin-2) or vehicle (PBS) for 2 weeks employing subcutaneous osmotic minipumps. Skeletal muscle protein identification and quantification were performed by LC-MS/MS using a Data-Independent Acquisition (DIA)-Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH) method. SWATH/MS quantitative analysis identified that relaxin-2 significantly decreased 95 proteins and significantly increased 32 proteins in rat skeletal muscle when compared to control rats. From these, 34 proteins were associated with muscle function, myogenesis, muscle differentiation and/or regeneration, 20 are mitochondrial proteins (six from the complexes of the electron transport chain), and 10 proteins participate in glucose metabolism. Qualitative data-dependent workflow analysis identified 35 proteins exclusive to the skeletal muscle of the relaxin-2-treated group: eight proteins related to processes of skeletal muscle function (size, ion homeostasis or organization of caveolae structures and cytoskeleton) and myogenesis, and two proteins involved in muscle differentiation. Our work highlighted for the first time the role of relaxin-2 in crucial processes of muscle physiology and energetic metabolism, which could influence several processes involved in myopathy and CV.

Indexed as

GlucoseMitochondriaMuscle, SkeletalProteomeRelaxinAnimalsHumansMaleProteomicsRatsRats, Sprague-DawleyGlucoseProteomeRelaxinRLN2 protein, humanenergetic metabolismglucose transportmitochondrial respirationmyogenesisproteomeproteomicsrelaxin‐2serelaxinskeletal muscle

Identifiers

PMID42742485
PMCPMC13576747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.